Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting

Theralase Technologies Inc., a clinical stage pharmaceutical company, announced that its interim clinical data will be presented at the 2025 American Urological Association (AUA) Annual Meeting. The abstract, titled "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ," will feature at a Podium Session in Las Vegas.

The data comes from Theralase's international Phase II study focusing on BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Dr. Girish Kulkarni will present the findings. The study highlights the safety and efficacy of light-activated Ruvidar™, with some patients showing sustained response over three years.

Chief Scientific Officer Arkady Mandel emphasizes the strong safety profile and long-lasting response, while CEO Roger DuMoulin-White notes the significance of the research. Theralase plans to market this innovative technology to the urological community by 2027, following regulatory approvals.